RNAZ - Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered | Benzinga
TransCode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 40.6% to $0.84 during Monday’s session after the company disclosed plans for a potential reverse stock split in an open letter to its shareholders. The proposal arises from the company’s failure to meet the Minimum Bid Requirement, as its common stock did not close at $1.00 or more for any ten-day period ending May 6.
Nasdaq has consequently notified TransCode Therapeutics of potential delisting, prompting the company to seek shareholder approval for the reverse split. In the event of a reverse split, the Board of Directors would be authorized to take action if they believe it serves the best interests of both the company and its shareholders.
While ...
RNAZ) Stock Is Getting Hammered>Full story available on Benzinga.com